DGAP-News: CO.DON AG and GENERIUM JSC sign license agreement to out-license co.don chondrosphere(R) to Russia

CO.DON AG and GENERIUM JSC sign license agreement to out-license co.don chondrosphere(R) to Russia

Berlin / Teltow, June 03, 2019 - CO.DON AG and GENERIUM JSC have now signed the license agreement regarding the out-licensing of the matrix-associated product co.don chondrosphere(R) for the Russian market, thereby implementing the corresponding term sheet signed in February 2019. GENERIUM JSC is a leading biopharmaceutical company in Russia focusing on advanced therapy medicinal products (ATMPs) and various recombinant drugs. In addition to out-licensing, the license agreement also includes consulting services, training and knowledge transfer by appropriately qualified CO.DON AG employees. The training of the Russian specialists will begin today in the CO.DON production facilities in Teltow. In addition to the actual instruction in the production of pharmaceuticals, they are also trained in aspects of quality control and quality assurance.

Ralf Jakobs, CEO of CO.DON AG: "We are pleased to inform our shareholders and the market about the conclusion of our license agreement for the Russian market. We are sure that we have found a very experienced partner in GENERIUM JSC who is well established in the Russian market and look forward to the cooperation ahead of us. This was already characterized in the negotiations by high professionalism and constructiveness. We assume that this will be a more than fruitful cooperation for both sides. At the same time, we hope and work on granting further licenses for other markets, also and especially non-European markets, for which we consider such an award to be reasonable and economically effective for CO.DON AG. In the economic area of the European Union, we will, based on our EU-wide approval, continue to expand our market presence in accordance with our strategy in our own sales and with partners. The first license of CO.DON AG, which has now been awarded, as well as the distribution agreements concluded to date, contribute to our positive financial outlook and cash return rate for the future".

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs (Spokesman), Tilmann Bur (COO).

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de